Medtronic Agrees to Pay $268 Million Over Recalled Leads

Medtronic, Inc. has recently agreed to pay $268 million to settle claims
involving their recalled
Sprint Fidelis leads used in internal cardiac defibrillators. The lead had a higher incidence
of fracturing causing the device to go off, shocking victims numerous
times unnecessarily.

Our firm currently represents hundred of patients that have or had the
recalled leads and are pleased to make this announcement.

The information on this website is for general information purposes only.
Nothing on this site should be taken as legal advice for any individual
case or situation. This information is not intended to create, and receipt
or viewing does not constitute, an attorney-client relationship.

x

⚠

Your browser is out of date. To get the full experience of this website,
please update to most recent version.